In a peculiar case, a 62-year-old man from Germany has reportedly received 217 COVID-19 vaccine doses, defying medical advice. The man has not suffered any adverse effects.
What Happened: The man, who chose to remain anonymous, received the vaccines privately over a period of 29 months, reported BBC on Tuesday. Researchers from the University of Erlangen-Nuremberg, who conducted the study, found no evidence of fatigue in the man’s immune system, despite concerns about overstimulation from repeated doses.
Dr. Kilian Schober, from the university’s microbiology department, said, “We learned about his case via newspaper articles. We then contacted him and invited him to undergo various tests in Erlangen. He was very interested in doing so.”
The man provided fresh blood and saliva samples, and the researchers also tested some of his frozen blood samples from previous years. The researchers collected evidence for 130 of the jabs, and although an investigation was opened with allegations of fraud, no criminal charges were brought.
Dr. Schober emphasized that the study’s results do not endorse hyper-vaccination as a strategy to enhance adaptive immunity. The researchers also stated that their findings were insufficient for making far-reaching conclusions or recommendations for the general public.
Why It Matters: This case raises questions about the potential risks and benefits of receiving multiple COVID-19 vaccine doses. The study’s findings could add to the ongoing global conversation about vaccine safety and efficacy, particularly in light of concerns about vaccine safety signals in older people and allegations of misleading efficacy claims by vaccine manufacturers.
The study also comes amid reports of contaminated vaccines, raising concerns about the overall safety and quality of COVID-19 vaccines.
Read Next: This Company Is Bringing Medical Marijuana Telehealth To Over Half The U.S.
Image via Shutterstock
Engineered by Benzinga Neuro, Edited by Pooja Rajkumari
The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.